Feasibility of Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a pilot study.

Feasibility of Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a pilot study. - Feasibility of Ruxolitinib in steroid-refractory GVHD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021349

Enrollment

Registered

2016-03-07

Start date

2016-03-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

corticosteroid-refractory graft-versus-host disease

Interventions

ruxolitinib 5mg, twice a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: steroid refractory GVHD age; 20-70 years

Exclusion criteria

Exclusion criteria: 1) with active infection 2) w/o informed consent 3) CCr<10 ml/min

Design outcomes

Primary

Measure	Time frame
response rete of GVHD adverse effect	—

Countries

Japan

Contacts

Public ContactYasushi Onishi

Tohoku University Hospital Hematology-Rhumatology

yonishi@med.tohoku.ac.jp022-717-7165

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026